Companies › Intuitive Surgical
1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IS-001 filricianine Near-infrared fluorescent imaging agent for intraoperative visualization of ureteral struc | – | Phase 3 | Ureter Injury | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07346066 | IS-001 filricianine | Phase 3 | Ureter Injury | Other | Apr 2027 |
Cash and short-term investments of $4.0bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Sound Pharmaceuticals Palvella Therapeutics Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.